ALT · Altimmune, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $5.0K | $5.0K | $5.0K | - | $5.0K | $5.0K | $5.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $16.19M | - | $14.96M | $17.24M | $15.83M | - | $19.80M | $21.16M | $21.49M | - |
| SG&A | $8.05M | - | $5.90M | $5.69M | $5.99M | - | $4.97M | $5.59M | $5.31M | - |
| Total Operating Expenses | $24.24M | - | $20.86M | $22.93M | $21.82M | - | $24.77M | $26.75M | $26.80M | - |
| D&A | $23.0K | - | - | - | $29.0K | - | - | - | $107.0K | - |
| Operating Income | ($24.24M) | - | ($20.86M) | ($22.92M) | ($21.82M) | - | ($24.77M) | ($26.75M) | ($26.79M) | - |
| Interest Expense | $1.07M | - | $495.0K | $264.0K | $1.0K | - | $6.0K | $1.0K | $1.0K | - |
| Income Tax | - | - | - | - | ($681.0K) | - | $0 | $0 | $0 | - |
| Net Income | ($22.56M) | - | ($19.01M) | ($22.15M) | ($19.57M) | - | ($22.84M) | ($24.64M) | ($24.39M) | - |
| EPS - Basic | ($0.18) | - | ($0.21) | ($0.27) | ($0.26) | - | ($0.32) | ($0.35) | ($0.34) | - |
| EPS - Diluted | ($0.18) | - | ($0.21) | ($0.27) | ($0.26) | - | ($0.32) | ($0.35) | ($0.34) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $97.60M | $43.76M | $61.24M | $183.10M | $49.10M | $36.93M | $31.47M | $57.13M | $78.98M | $135.12M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.53M | $2.72M | $4.80M | $851.0K | $1.08M | $211.0K | $1.13M | $2.69M | $3.76M | $2.07M |
| Current Assets | $334.68M | $278.19M | $216.62M | $188.42M | $155.26M | $137.25M | $145.76M | $171.19M | $187.51M | $209.63M |
| Total Assets | $335.63M | $279.93M | $218.45M | $190.35M | $157.26M | $139.31M | $147.86M | $173.35M | $188.36M | $210.64M |
| Current Liabilities | $11.32M | $15.00M | $12.61M | $9.22M | $9.80M | $10.47M | $8.64M | $15.15M | $11.33M | $12.14M |
| Long-term Debt | $34.51M | $34.29M | $14.45M | $14.33M | - | - | - | - | - | - |
| Total Liabilities | $51.64M | $55.04M | $32.85M | $28.98M | $15.10M | $15.80M | $14.49M | $20.82M | $15.42M | $16.54M |
| Stockholders' Equity | $283.99M | $224.89M | $185.60M | $161.37M | $142.16M | $123.51M | $133.38M | $152.53M | $172.94M | $194.10M |
| Retained Earnings | ($672.05M) | ($649.48M) | ($622.13M) | ($603.11M) | ($580.97M) | ($561.39M) | ($538.21M) | ($515.37M) | ($490.73M) | ($466.33M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($20.94M) | - | - | - | ($16.84M) | - | - | - | ($16.36M) | - |
| Investing Cash Flow | ($3.69M) | - | - | - | ($5.10M) | - | - | - | ($39.52M) | - |
| Financing Cash Flow | $78.47M | - | - | - | $34.12M | - | - | - | ($261.0K) | - |
| CapEx | $21.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($20.96M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -417180.0% | -458440.0% | -436300.0% | - | -495340.0% | -534900.0% | -535880.0% | - |
| EBITDA margin | - | - | - | - | -435720.0% | - | - | - | -533740.0% | - |
| Net margin | - | - | -380280.0% | -442920.0% | -391500.0% | - | -456900.0% | -492800.0% | -487880.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.93 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 299200.0% | 344720.0% | 316540.0% | - | 396060.0% | 423100.0% | 429740.0% | - |
| SG&A / Revenue | - | - | 118080.0% | 113820.0% | 119860.0% | - | 99380.0% | 111900.0% | 106240.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.7% | - | -8.7% | -11.6% | -12.4% | - | -15.5% | -14.2% | -13.0% | - |
| Return on equity | -7.9% | - | -10.2% | -13.7% | -13.8% | - | -17.1% | -16.2% | -14.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 29.56 | 18.55 | 17.18 | 20.44 | 15.85 | 13.11 | 16.87 | 11.30 | 16.55 | 17.26 |
| Quick ratio | 29.56 | 18.55 | 17.18 | 20.44 | 15.85 | 13.11 | 16.87 | 11.30 | 16.55 | 17.26 |
| Cash ratio | 8.62 | 2.92 | 4.86 | 19.86 | 5.01 | 3.53 | 3.64 | 3.77 | 6.97 | 11.13 |
| Leverage | ||||||||||
| Debt / Equity | 0.12 | 0.15 | 0.08 | 0.09 | - | - | - | - | - | - |
| Debt / Assets | 0.10 | 0.12 | 0.07 | 0.08 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -22.7x | - | -42.1x | -86.8x | -21815.0x | - | -4127.8x | -26745.0x | -26794.0x | - |
| Equity multiplier | 1.18 | 1.24 | 1.18 | 1.18 | 1.11 | 1.13 | 1.11 | 1.14 | 1.09 | 1.09 |
| Liabilities / Assets | 0.15 | 0.20 | 0.15 | 0.15 | 0.10 | 0.11 | 0.10 | 0.12 | 0.08 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.3x | - | 1.8x | 2.0x | 2.7x | - | 3.3x | 3.1x | 4.2x | - |
| P / S | - | - | 67421.2x | 63063.6x | 75547.7x | - | 87292.1x | 94329.4x | 144152.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 0.0% | 0.0% | 0.0% | - | -98.6% | -16.7% | -76.2% | - |
| Revenue CAGR (3y) | - | - | 35.7% | -14.5% | -46.1% | - | -68.3% | -66.9% | -81.9% | - |
| Revenue CAGR (5y) | - | - | -72.1% | -63.0% | -70.4% | - | -62.2% | -68.6% | -71.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.1% | - | 15.8% | 14.3% | 18.6% | - | -9.9% | -48.5% | -23.1% | - |
| Net income growth (YoY) | -15.3% | - | 16.8% | 10.1% | 19.8% | - | -10.5% | -53.4% | -21.5% | - |
| EPS growth (YoY) | 30.8% | - | 34.4% | 22.9% | 23.5% | - | 17.9% | -9.4% | 12.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 99.8% | 82.1% | 39.2% | 5.8% | -17.8% | -36.4% | -11.3% | -9.1% | 3.1% | 4.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$500.0K totalGrant$500.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Altimmune against the 5 most active filers in the same SIC group.